Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : COMS & the Ghost of USRX w/ other STUFF -- Ignore unavailable to you. Want to Upgrade?

To: DMaA who wrote (20688)	4/17/2000 11:35:00 AM
From: Scrapps	Respond to of 22053

Any opinions on this? Anyone? ......... biz.yahoo.com Major Progress in Aggressive Cancer Type Reported for Genta's Lead Antisense Drug LEXINGTON, Mass., April 14 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA - news) announced today the publication of a paper that reports a new treatment strategy for an aggressive form of cancer, known as Merkel cell tumor. Using a preclinical model of human cancer transplanted into mice, the study showed that treatment with Genta's lead antisense compound, currently known as G3139, was both highly effective and superior to cisplatin (Platinol(TM) Bristol Myers Squibb), a drug that is clinically used for treatment of this disease. The study was conducted at the University of Vienna and was published in the April issue of The Journal of Investigative Dermatology. The study directly compared the effectiveness of cisplatin with that of G3139 in mice implanted with human cancer cells. After 28 days, cisplatin treatment had no effect in reducing tumor size compared with controls, whereas G3139 resulted in a 90% reduction in average tumor size. Moreover, some of the G3139-treated animals were apparently cured of the disease. G3139 also appeared to be better tolerated; whereas cisplatin treatment resulted in an average weight loss of 10%, animals treated with G3139 showed normal or improved weight throughout the period of cancer treatment. Dr. Robert E. Klem, Genta's Chief Technical Officer noted, ``In the past, this form of human cancer has been notoriously difficult to treat. The new information reported by this group extends the large body of Genta's experimental data, which collectively shows that G3139 can potentiate the antitumor activity of many anticancer drugs.' Merkel cell carcinomas, as well as many prevalent forms of human cancers, express high levels of Bcl-2 protein, which can protect cancer cells from being killed by conventional chemotherapy. In the study announced today, antitumor activity was closely correlated with G3139-induced reduction in Bcl-2 protein within the cancer cells -- a finding that affirms the importance of this mechanism of action. Genta Incorporated is a biopharmaceutical company with a product portfolio focused on anticancer therapy, including its Anticode(TM) (antisense) platform technology, as well as other important anticancer products. The Company's lead compound, G3139, has received ``Fast Track' designation from the Food and Drug Administration and has recently entered Phase III trials in patients with advanced melanoma. Genta aims to become a direct marketer of its pharmaceutical products in the United States. For more detailed information about Genta, please visit the company's website at genta.com. The statements contained in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. Without limiting the foregoing, the words ``anticipates,' ``believes,' ``expects,' ``intends,' ``may' and ``plans' and similar expressions are intended to identify forward-looking statements. The Company intends that all forward-looking statements be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events, but are subject to many risks and uncertainties, which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward-looking statements. For example, the results obtained in pre-clinical or clinical studies may not be indicative of results that will be obtained in future clinical trials; there can be no assurance that clinical testing of the Androgenics technology will occur; Genta has not successfully completed human clinical trials of a product based on antisense technology; and delays in the completion of clinical trials as a result of delays in patient enrollment or other factors may occur. Further examples of such risks and uncertainties also include, but are not limited to: the obtaining of sufficient financing to maintain the Company's planned operations; the timely development, receipt of necessary regulatory approvals and acceptance of new products; the successful application of the Company's technology to produce new products; the obtaining of proprietary protection for any such technology and products; the impact of competitive products and pricing and reimbursement policies; and the changing of market conditions. The Company does not undertake to update forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement and other factors detailed in the Company's reports filed with the Securities and Exchange Commission. SOURCE: Genta Incorporated --------------------------------------------------------- On another note: Who the heck is this Wibbelsman guy and how did he get access to my trading accounts? Is that his real name I wonder or is that the way Elmer Fud pronounces it?